Further supporting this hypothesis, intravenous administration of human recombinant ApoA-I Milano has been shown to significantly reduce Aβ accumulation in the brains of APP23-transgenic mice, a well-established model of AD [127]. This evidence concerns the gene APOA1 and Alzheimer disease.